Evidence map›Paper›PMID 42249838›Full record

ArticleJournal of medicinal chemistry2026

Hit-to-Lead Optimization of Energy-Coupling Factor (ECF) Transporter Inhibitors as Novel Antibiotic.

Ioulia Exapicheidou, Aleksei Tsarenko, Lena Zeller, Hamza Ibrahim, Carole Baumann, Atanaz Shams, Patrick A Hoffmann, Yue Li, Andreas M Kany, Jennifer Hermann and 6 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ioulia ExapicheidouHelmholtz Institute for Pharmaceutical Research (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E 8.1, Saarbrücken, Saarland D-66123, Germany.
Aleksei TsarenkoGroningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Nijenborgh 4, Groningen 9747AG, The Netherlands.
Lena ZellerHelmholtz Institute for Pharmaceutical Research (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E 8.1, Saarbrücken, Saarland D-66123, Germany.
Hamza IbrahimHelmholtz Institute for Pharmaceutical Research (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E 8.1, Saarbrücken, Saarland D-66123, Germany.
Carole BaumannHelmholtz Institute for Pharmaceutical Research (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E 8.1, Saarbrücken, Saarland D-66123, Germany.
Atanaz ShamsHelmholtz Institute for Pharmaceutical Research (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E 8.1, Saarbrücken, Saarland D-66123, Germany.
Patrick A HoffmannHelmholtz Institute for Pharmaceutical Research (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E 8.1, Saarbrücken, Saarland D-66123, Germany.
Yue LiData Driven Drug Design, Center for Bioinformatics, Saarland Informatics Campus, Saarland University, Saarbrücken 66123, Germany.
Andreas M KanyHelmholtz Institute for Pharmaceutical Research (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E 8.1, Saarbrücken, Saarland D-66123, Germany.
Jennifer HermannHelmholtz Institute for Pharmaceutical Research (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E 8.1, Saarbrücken, Saarland D-66123, Germany.ORCID 0000-0003-3398-9938
Dirk J SlotboomGroningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Nijenborgh 4, Groningen 9747AG, The Netherlands.ORCID 0000-0002-5804-9689
Rolf MüllerHelmholtz Institute for Pharmaceutical Research (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E 8.1, Saarbrücken, Saarland D-66123, Germany.ORCID 0000-0002-1042-5665
Andrea VolkamerHelmholtz Institute for Pharmaceutical Research (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E 8.1, Saarbrücken, Saarland D-66123, Germany.ORCID 0000-0002-3760-580X
Mostafa M HamedHelmholtz Institute for Pharmaceutical Research (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E 8.1, Saarbrücken, Saarland D-66123, Germany.ORCID 0000-0002-7374-6992
Eleonora DiamantiHelmholtz Institute for Pharmaceutical Research (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E 8.1, Saarbrücken, Saarland D-66123, Germany.ORCID 0000-0001-8392-5575
Anna K H HirschHelmholtz Institute for Pharmaceutical Research (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E 8.1, Saarbrücken, Saarland D-66123, Germany.ORCID 0000-0001-8734-4663

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiparameter optimization of a previously identified class of inhibitors of the energy-coupling factor (ECF) transporters enabled the confirmation of

Indexed as

Anti-Bacterial AgentsMembrane Transport ProteinsAnimalsEnterococcus faeciumGram-Positive BacteriaHumansMicrobial Sensitivity TestsStructure-Activity RelationshipZebrafishAnti-Bacterial AgentsMembrane Transport Proteins

Identifiers

PMID42249838
PMCPMC13312448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.